1/92
lee, sivers
mab overview: what it does, parts
IgG that were designed to have a very specific target that is important for the survival and growth of cancer cells
bind to extracellular receptors or its natural ligand to prevent intracellular signaling
Parts:
Fab: fragment antigen-binding
Fc: fragment crystallizable
mab mechanisms (4)
direct apoptosis
Antibody-dependent cellular cytotoxicity
Complement-dependent cytotoxicity
anti VEGF antibiotics
Biosimilars
Drug that is highly similar, but not identical to a biologic drug due to differences in the manufacturing process
what is CD20 and what is it involved in(3)
A transmembrane calcium channel
Involved in B cell activation, proliferation, and maturation
what does anti- CD20 mabs do and what indications are they used for
Binds to CD20 on B cell surface and exerts (on B cells)
used for Lymphomas, chronic lymphocytic leukemia (CLL)
Anti-CD20 MAbs drugs
Rituximab
Obinutuzumab
Ofatumumab
EGFR Inhibitors drugs, moa, indication
Cetuximab and Panitumumab
moa: Block phosphorylation and activation of receptor-associated kinases
Colorectal cancer (EGFR-expressing without RAS mutations)
Cetuximab toxicity and BBW
Dermatologic toxicity/rash
Boxed warnings: Infusion reactions, cardiopulmonary arrest
Panitumumab BBW
BBW: Dermatologic toxicity/rash
Dermatologic Toxicity from Cetuximab prophylaxis and treatment
prophylaxis: general stuff like hydration, no sun, use alc free mostiruzers
treatment: topical steroids, topical antibiotics, systemic steroids, or tetracyclines
might need to hold dose based on severity*
HER-2 Inhibitors drugs, moa
drugs: Trastuzumab (Herceptin®); Pertuzumab (Perjeta®)
moa: Bind to extracellular domain of HER2 protein and inhibit downstream signaling, inducing apoptosis
HER-2 inhibitors tox and BBW
Boxed warning: Cardiotoxicity - LV dysfunction/heart failure (high risk esp. with anthracycline)
Boxed warning: Embryo-fetal toxicity
Boxed warning: pulmonary toxicity (except for pertuzumab) Infusion reaction (IV formulations only), hypersensitivity (all formulations
VEGF drugs, moas and indication
Bevacizumab binds to VEGF (ligand)
Ramucirumab binds to VEGFR-2 (receptor)
colorectal cancers
CTLA-4 inhibitors (immune checkpoint inhibitor)
Ipilimumab (Yervoy)
PD-1 inhibitors (immune checkpoint inhibitor)
Nivolumab (Opdivo)
Pembrolizumab (Keytruda)
PD-L1 inhibitors (immune checkpoint inhibitor)
Atezolizumab (Tecentriq)
Durvalumab (Imfinzi)
Antibody Drug Conjugates moa
MAbs are linked with a cytotoxic payload to increase cytotoxicity of mAbs, while maintaining specificity for a tumor cell target
Ado-trastuzumab emtansine BBW and cytotoxic payload
cardiotoxicity
cytotoxic payload: DM1 (microtubule inhibitor)
Fam-Trastuzumab Deruxtecan (Enhertu®) BBW and cytotoxic payload
interstitial lung disease
cytotoxic payload: DXd (topoisomerase I inhibitor)
Inotuzumab ozogamicin BBW and cytotoxic payload
Hepatotoxicity (risk of veno-occlusive disease), increased risk of non-relapse mortality post-stem cell transplant
cytotoxic payload: Calicheamicin derivative (antitumor antibiotic)
Gemtuzumab ozogamicin BBW and cytotoxic payload
Boxed warning: Hepatotoxicity (risk of veno-occlusive disease)
cytotoxic payload: Calicheamicin derivative (antitumor antibiotic)
supportive care for Gemtuzumab ozogamicin and Inotuzumab ozogamicin
Premedicate with corticosteroid, antipyretic, and antihistamine
Polatuzumab vedotin cytotoxic payload and supportive care
cytotoxic payload:
Premed with antihistamine, antipyretic
Brentuximab vedotin and Polatuzumab vedotin cytotoxic payload
Monomethyl auristatin E (MMAE)
Bispecific T-cell Engager (BiTE) moa and indications
Antibodies that target one tumor antigen and one immune-related molecule (CD3 on T cells)
used for B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, multiple myeloma
Blinatumomab binds where and to what; and what class?
Binds to CD19 on B-cells and CD3 on T-cells
Anti-CD19 BiTE
Blinatumomab BBW and supportive care
Cytokine release syndrome, neurotoxicity
give corticosteroids before each dose and hospitalization is recommended for atleast first 2 doses
what does dysregulation of RTKs lead to?
cancer cell survival
Mechanisms of RTKs in cancer
gain of function mutations→ persistant activation
amplification/overexpression of receptors
chromosomal rearrangements
what type of drugs are Tyrosine Kinase inhibitors usually?
small molecule drugs which involve mutations within RTKs
Targets of TKIs in hematological cancers
BCR-ABL
FLT3
BCR-ABL inhibitor mechanism and target
inhibit BCR-ABL tyrosine kinase, blocking cancer cell proliferation and inducing apoptosis
target is the BCR-ABL fusion oncoprotein
Resistance to BCR-ABL inhibtors (primary and secondary)
primary: not as common; defined as no remission in 3-18 months after initiation
secondary: T315I mutation
if a pt has T315I mutation, which drugs can work?
ponatinib and asciminib
Imatinib class and indication
1st gen BCR-ABL inhibitor (TKIs)
for Ph+ CML, Ph+ ALL, gastrointestinal stromal tumors (GIST)
Imatinib couseling pt and toxcity
take with food
tox: fluid retention (periorbital edema) fluid around eyes
Dasatinib class and indication
2nd generation BCR-ABL inhibitor
indication: Ph+ CML, Ph+ ALL
Dasatinib DDI and tox
Do not administer PPIs and H2RAs concomitantly with dasatinib
tox: fluid retention (pleural or pericardial effusions), pulmonary arterial hypertension (PAH),
Nilotinib class and indication
2nd generation BCR-ABL inhibitor
Ph+ CML
Nilotinib DDI, couseling pt, tox, BBW
DDI: H2RAs and PPIs
take on empty stomach
Toxicities: metabolic syndrome
BBW: QTc interval prolongation and sudden death
Bosutinib class and indication
2nd generation BCR-ABL inhibitor
Indications: Ph+ CML
Bosutinib couseling pt, DDI and tox
DDI: H2RAs and PPIs
take with food
tox: diarrhea, N/V (moderate/high emetogenic potential)
Ponatinib class and indication
3rd generation BCR-ABL inhibitor
for Ph+ CML, Ph+ ALL
Ponatinib couseling and BBW
take with food
BBW: arterial occlusive events, VTE
Asciminb class, moa, and indication
STAMP Inhibitor
allosteric inhibiton by targeting the ABL myristoyl pocket)
indication: Ph+ CML (new or if it came back diagnosis)
Asciminb couseling pt and tox
take without food
tox: pancreatitis, hypertension
FLT3 mutations, types, and which inhibitors work for those types
FLT3 mutations are activating mutations that promote leukemic cancer cell survival and proliferation
1) Internal tandem duplication (ITD)
Type 2 inhibitors only
2) Tyrosine kinase domain (TKD)
type 1 and type 2 inhibitors
Type 1 and 2 inhibitors diff how
Type 1→ bind only in active conformation
Type 2→ bind only in inactive conformation
Midostaurin class and indication
type 1 FLT3 inhibitor
newly diagnosed FLT3-positive AML in combo w/standard chemotherapy induction & consolidation
Midostaurin tox
gastrointestinal (N/V, high-moderately emetogenic), QTc interval prolongation
Gilteritinib class and indication
type 1 FLT3 Inhibitor
relapsed/refractory FLT3-positive AML
Gilteritinib tox
Differentiation syndrome (BBW), QTc interval prolongation, pancreatitis, posterior reversible encephalopathy syndrome (PRES)
Quizartinib class and indication
type 2 FLT3 inhibitor
newly diagnosed FLT3 internal tandem duplication (ITD) positive AML in combo w/standard chemotherapy induction, consolidation, and maintenance
Quizartinib tox, BBW, monior and imp
QTc interval prolongation, Torsades de points and cardiac arrest (BBW),
so monitor w ECG
REMS program à BBW for QTc interval prolongation, Torsade's de Pointes, and cardiac arrest
EGFR inhibitor moa and how
Gain-of-function mutations from exon 19 or exon 21 L858R
EGFR TKIs vs mabs
TKIs: bind to intracellular kinase domain of the EGFR (ErbB-1) and block the binding of ATP,
mabs: inhibit the extracellular ligand binding-site of EGFR
Resistance to EGFR inhibitors and which is an exception
T790M mutation→ resistance to all commercially available EGFR TKIs except osimertinib
EGFR inhibitors tox
Derm related bc increased chemokines and inflammation
NOT ACNE
Erlotinib class, indication and DDI
EGFR inhibitor for pancreatic + NSCLC
DDI: PPIs, separate from H2RAs
Lazertinib class, imp point, tox
EGFR inhibitor for NSCLC in combo w/ amivantamab NEVER alone
tox: VTE: PPX anti- coagulation for 1st 4 months)
ALK inhibitors moa
Formation of EML4-ALK fusion oncoprotein makes the ALK, so inhibiting ALK→ induces apoptosis and blocking cancer cell proliferation
ALK inhibitors indication and one med with 2 indications
Metastatic ALK NSCLC
Crizotinib→ Metastatic ALK or ROS1 (+) NSCLC
HER2 inhibitors moa
proto-oncogene overexpressed; HER2 TKIs bind to the intracellular tyrosine kinase domain of HER2 (ErbB-2),
Lapatinib class and indication
HER2 inhibitor
metastatic HER2 positive breast cancer
Lapatinib tox and BBW
tox: cardiac (decreases in LVEF), diarrhea,
BBW: hepatotoxicity
Neratinib class and indication
HER2 inhibitor
extended adjuvant therapy in high risk, HER2 positive breast cancer
Neratinib tox and supportive care
tox: diarrhea,
supportive care: Antidiarrheal prophylaxis
BCL2 inhibitor moa
binds directly to the BCL2 protein→ leading to apoptosis
Venetoclax class, indication
BCL2 inhibitor
acute myeloid leukemia (AML) in adults 75 years or older or with comorbidities that prevent intensive chemo,
Venetoclax dosing, tox
concomitant use with moderate or strong CYP3A4 inhibitor
ramp up dosing
tox→ tumor lysis syndrome, bone marrow suppression,
Idelalisib class and indication
Selective PI3Kδ(delta) Inhibitor
Chronic lymphocytic leukemia (CLL) w/rituximab
Idelalisib bbw
Hepatotoxicity, diarrhea/colitis, pneumonitis, infections and intestinal perforation
VERY TOXiIC
Alpelisib class and indication
Selective PI3K⍺ inhibitor
PIK3CA-mutated, HR (+), HER2 (-) metastatic breast cancer
Alpelisib tox
hyperglycemia
think a1c bc PI3Ka
Inavolisib class and indication
Selective PI3K⍺ inhibitor
PIK3CA-mutated, HR (+), HER2 (-) metastatic breast cancer in combo with fulvestrant + palbociclib
Inavolisib tox
Stomatitis, Hyperglycemia
CDK 4/6 inhibitors drugs
Ribociclib, Palbociclib, Abemaciclib
CDK 4/6 inhibitors inidications
HR-positive, HER2- negative, advanced or metastatic breast cancer
PARP inhibitors moa
bind to PARP and prevent the repair of single-strand DNA breaks, leading to double stranded breaks
PARP inhibitors drugs, indications, and tox
Olaparib and Talazoparib
both for BRAC mutated cancers
taalazoparib→ needs to be metastized breast cancer
olarparib→ can use against any
tox→ secondary malignancies
BRAF/MEK inhibitors drugs and mutation
BRAF→ Dabrafenib; Encorafenib, Vemurafenib
MEK→ Trametinib; Binimetinib, Cobimetinib
need BRAF V600E/K mutations
BRAF/MEK inhibitors specifc indications
Vemurafenib/Cobimetinib → mutated melanoma only
Encorafenib/ Binimetinib→ mutated melanoma, metastatic NSCLC
Dabrafenib/ Trametinib→ mutated melanoma, non- small cell lung cancer, advanced solid tumors
BRAF/MEK tox
Dermatologic (rash, skin cancers) - DLT
Pyrexia
IDH mutation
normal: isocitrate to ⍺-ketoglutarate
Mutations in IDH enzymes convert ⍺-KG to 2-hydroxyglutarate (2-HG)
IDH inhibitors drugs, indications, tox
Ivosidenib→ IDH1 mutated AML
Enasidenib→ IDH2 mutated
tox for both→ differentiation syndrome